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Attenuated endothelial function is 
associated with cardiovascular risk 
factors and is considered as preclini-
cal sign of cardiovascular disease. 
Pregnancy related complications such 
as hypertensive disorder in pregnancy, 
preeclampsia and gestational diabetes 
and cardiovascular disease share many 
risk factors. This study was undertaken 
to explore endothelial function in nor-
mal pregnancy as well as in pregnancy 
related complications. Endothelial 
function was assessed with brachial 
artery flow mediated dilation as a 
part of the on-going population based 
Cardiovascular Risk Factors in Young 
Finns Study and in the Complicated 
Pregnancy Study in Kuopio University 
Hospital conducted in 2003-2008.
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ABSTRACT 
Preeclampsia and cardiovascular disease, and also gestational diabetes and type 2 diabetes 
share the same risk factors (genetic predisposition, obesity, metabolic syndrome, 
hyperlipidemia, high blood pressure) and probably at least partly the same 
pathophysiology. Knowledge of how normal or complicated pregnancy affects the 
endothelium can help in evaluating the risks for future cardiovascular disease and being 
able to provide advice on how to prevent or postpone the disease.  
This study was undertaken to explore endothelial function in normal pregnancy as well 
as in pregnancy related complications that are related to endothelial damage. During 
pregnancy the increase in nitric oxide bioavailability enhances endothelial function despite 
the presence of marked hyperlipidemia and inflammation. Even in pregnancy related 
hypertensive and metabolic disorders, i.e.  mild to moderate preeclampsia and gestational 
diabetes, endothelial function was not impaired when measured noninvasively from the 
brachial artery. Thus brachial artery flow mediated dilation does not seem to be suitable 
for clinical use for example in predicting preeclampsia or detecting the endothelial 
damage in current disease according to our results. Pregnancy related complications are 
known risk factors for future diseases.  Hypertension in pregnancy and preeclampsia 
carry the risk for hypertension and cardiovascular diseases later in life. Approximately 30 
% of the women with gestational diabetes but almost none of those with normal glucose 
tolerance during pregnancy will develop type 2 diabetes in 15 years surveillance. We 
found that soon after parturition, women with previous gestational diabetes exhibit 
marked cardiovascular risk factors, such as obesity and elevated serum lipid and glucose 
concentrations. Although these risk factors were not associated with endothelial damage, 
these women have an increased risk of developing diabetes mellitus type 2 and 
cardiovascular disease. An intervention at this stage may be highly advantageous when 
arteriosclerosis is still preventable with lifestyle changes and, if required, other 
interventions. 
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TIIVISTELMÄ 
 
Tutkimuksen tavoitteena oli tarkastella verisuonten sisäkerroksen eli endoteelin toimintaa 
normaaliraskaudessa ja sellaisissa raskauksissa, joissa synnyttäjällä oli raskausmyrkytys, 
raskauden aikainen verenpainetauti tai raskausajan diabetes. Verisuonten sisäkerroksen 
eli endoteelin toimintaa arvioitiin olkavarsivaltimosta mittaamalla ultraäänellä verisuonen 
laajenemista puristuksen jälkeen. Verisuonen endoteelin toiminta parani normaalin 
raskauden aikana. Verisuonet laajenivat lisääntyneen typpioksidipitoisuuden ansiosta 
parantaen näin kohdun verenkiertoa sikiötä varten. Raskaudenaikainen veren rasva-
arvojen voimakas nousu tai tulehdusta välittävien aineiden pitoisuuden lisääntyminen 
eivät huonontaneet verisuonten toimintaa raskauden aikana, vaikka ilman raskautta 
niiden tiedetään aiheuttavan verisuonen sisäkerroksen toimintahäiriöitä. 
Raskaudenaikaisen verenpainetaudin tai raskausmyrkytyksen ei todettu huonontavan 
olkavaltimon endoteelin toimintaa. Aiemmin on osoitettu, että naisen raskausajan 
verenpainetauti ja raskausmyrkytys lisäävät merkittävästi myöhempää verenpainetauti- ja 
sydän- ja verisuonisairausriskiä. Hyvässä hoitotasapainossa oleva raskausdiabetes ei 
heikentänyt verisuonten toimintaa. Raskausajan diabeteksen ajatellaan paranevan 
synnytyksen jälkeen, mutta näillä naisilla on todettu suurentunut todennäköisyys 
sairastua 1 tai 2 tyypin diabetekseen. Tutkimuksessamme raskauden ajan diabetesta 
sairastaneilla naisilla veren rasva- ja sokeriarvot sekä paino olivat merkittävästi koholla 
kolmen kuukauden kuluttua synnytyksestä verrattuina normaaliraskauden jälkeen 
tutkittuihin naisiin. Jo raskauden aikana tulisi antaa tietoa raskausajan komplikaatioiden 
pitkäaikaisvaikutuksista ja elämäntapaohjausta diabeteksen ja sydän- ja 
verisuonisairauksien ehkäisystä. 
 
 
Luokitus: 
Yleinen Suomalainen asiasanasto: Raskaus; verisuonet; endoteeli, pre-eklampsia, raskausdiabetes. 
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1 Introduction 
Sir Thomas Lauder Brunton first used amyl nitrite in the treatment of angina 
pectoris in 1867(Brunton. 1867). As a medical student, Brunton had become aware of 
the prior clinical findings of Benjamin Ward Richardson that inhaled amyl nitrite 
rapidly increased the activity of the heart(Richardson. 1864), and also the 
unpublished observations of Arthur Gamgee demonstrating that amyl nitrite greatly 
lessened ‘arterial tension’ in both animals and man. During the same period in 
which Brunton used amyl nitrite, another British physician, William Murrell, began 
using the organic nitrate, GTN, in the treatment of angina pectoris. With nitro-
glycerine therapy, patients would obtain relief from angina with some patients also 
reporting that their angina attack could be aborted by taking the drug at the very 
onset of symptoms(Murrel. 1897). Murrell’s discovery of NTG, the world’s first 
synthesized drug, for the treatment of angina pectoris is still in therapeutic use 140 
years later(Nossaman, et al. 2010). 
In pregnancy the endothelial production of nitric oxide (NO) is increased in the 
systemic and in the uterine vasculature in order to maintain adequate oxygen and 
nutrient supply to the growing fetus(Boeldt, et al. 2011). Several physiological 
changes take place during pregnancy: cardiac output increases, plasma volume 
increases, peripheral resistance falls, blood pressure first falls reaching its nadir in 
the second trimester, and then rises again with the approach of term. The metabolic 
changes include alterations in insulin sensitivity, requirements for insulin secretion 
increase, and there are elevated serum concentrations of lipids(An-Na, et al. 1995). 
The parasympathetic nervous system deactivates(Ekholm, et al. 1994) and a complex 
interplay of inflammatory events is regulated by both the innate and acquired 
immune systems(MacIntyre, et al. 2012). Sometimes these physiologic demands are 
excessive, and complications such as hypertension in pregnancy, preeclampsia and 
gestational diabetes appear. These complications are relatively common and usually 
reversible and forgotten after pregnancy. However these complications can be 
viewed as a canary in a coal mine, i.e. they are the first warning signs of looming 
chronic diseases. If a woman has suffered preeclampsia then the Framingham score 
based, calculated 10-year cardiovascular disease risk odds ratio is 1.31 (95% 
confidence interval 1.11 – 1.53) when compared to those with normal 
pregnancies(Fraser, et al. 2012). There is much evidence that pregnancy seems to 
expose those women who have reduced capacity of insulin secretion or who have 
insulin resistance and are at risk of developing diabetes later in life. Women with 
earlier gestational diabetes display an increased risk of developing type 2 diabetes 
compared with those who had a normoglycemic pregnancy (RR 7.43, 95% CI 4.79-
11.51)(Bellamy, et al. 2009) and in another study, the diabetes risk  was 40% in those 
with GDM in pregnancy over the ten subsequent years (Lauenborg, et al. 2004). In 
contrast, none of the women with normal glucose metabolism developed diabetes in 
six years follow-up(Järvelä, et al. 2006). Preeclampsia is associated with insulin 
resistance(Kaaja, et al. 1999) and may also increase the subsequent risk for 
diabetes(McDonald, et al. 2008). If it were possible to predict, diagnose and treat 
these pregnancy-related complications, this would reduce the morbidity of the 
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mothers and fetuses not only during pregnancy and shortly after birth, but could 
also have beneficial effects on their health far into the future. 
The aim of this thesis was to clarify the factors contributing to the vascular health of 
pregnant women. Normal pregnant women and women with pregnancy related 
complications such as hypertension, preeclampsia and gestational diabetes were 
examined during and after pregnancy. We assessed the endothelial function using 
flow mediated vasodilation (FMD) from brachial artery.  We further evaluated the 
concentrations of glucose, lipids, inflammatory markers and asymmetric 
dimethylarginine (ADMA) in these women and we estimated whether these markers 
were related to endothelial function. 
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2 Review of the literature 
2.1 THE VASCULAR ENDOTHELIUM AND ITS FUNCTIONS 
 
The arterial wall has 3 layers: the intima, including the endothelium, the media, and 
the adventitia (Figure 1). Each of these layers has individual roles in the systemic 
circulation. The endothelium is a monolayer of cells on blood and lymphatic vessels. 
The thin squamous type of epithelium was virtually invisible in light microscopy 
and initially considered as a nonessential cellophane-like sheet. Now the endothelial 
cells (ECs), have earned the profound respect of biologists and pathologists in the 
relatively short time of 50 years (Simionescu. 2007). 
 
 
Figure 1. The arterial wall. 
 
The endothelium is an active organ, and its functions are listed below and 
presented in figure 2. 
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The functions of endothelium. 
 
1. Regulation of vascular tone 
2. Regulation of vascular permeability 
3. Pro- and anticoagulant activity 
4. Contribution to the balance of pro- and anti-inflammatory mediators 
5. Role in generation of new blood vessels 
6. Interaction with circulating blood cells 
 
 
Figure 2. Functions of endothelium. eNOS endothelial nitric oxide synthase, NO nitric 
oxide, cGMP cyclic guanisine monophosphate, NF-κβ  nuclear factor κβ, VCAM-1 
vascular cell adhesion molecule -1, MCP-1 monocyte chemotactic protein-1. With 
permission from(Van der Oever, et al. 2010). 
 
Endothelial cells are heterogenic; the phenotype varies according to the 
requirements of the individual organ(Deanfield, et al. 2007). Endothelial cells receive 
and respond to signals from both surrounding cells and tissues and flowing blood. 
The response to a given stimulus may vary dramatically from one vascular bed to 
another.  Quiescent endothelial cells display the thromboresistant, anti-adhesive and 
vasodilatory phenotype, whereas activated endothelial cells have procoagulant, pro-
adhesive, and vasoconstricting properties. The normal relatively dilated state of the 
vascular wall is maintained mainly by nitric oxide(Aird. 2008). The principal 
5 
 
 
 
physiologic stimulus for endothelial NO synthesis is blood flow-induced shear 
stress. This process is called flow mediated vasodilation. 
2.2 ASSESSMENT OF ENDOTHELIAL FUNCTION 
 
Endothelial function can be evaluated via the following different approaches: (1) 
measurement of morphological and mechanical characteristics of the vascular wall 
(eg, intima media thickness, compliance, distensibility, and remodelling indexes); (2) 
determination of soluble endothelial markers (eg,von Willebrandt factor, 
thrombomodulin, adhesion molecules, plasminogen activator inhibitor complex and 
N-oxides); and (3) measurement of the endothelium-dependent regulation of 
vascular tone at focal sites of the circulation. Endothelial function can be measured 
in coronary arteries and in the peripheral vessels by measuring vasomotor function 
after intra-arterial infusion of vasoactive substances e.g. acetylcholine (ACh) which 
enhances the release of endothelial NO (Table 1.). The disadvantage of these 
methods is their invasive nature involving arterial cannulation. These tests are 
generally unsuitable for subjects who are at risk for atherosclerosis but who have no 
clinical symptoms or signs of disease(Raitakari, et al. 2000). For this reason, non-
invasive tests of endothelial function have been developed. Currently the main 
noninvasive techniques to assess endothelial functions are flow-mediated 
vasodilation (FMD) as measured by ultrasound of the brachial artery, pulse wave  
contour analysis (PCA), and finger plethysmography during postischemic 
hyperemia(PAT) (Table 2.). Other invasive and noninvasive methods for measuring 
coronary microvascular function have been recently reviewed, such as magnetic 
resonance imaging (MRI), positron emission tomography scanning (PET), CT 
scanning, single photon emission CT, Doppler echocardiography, Doppler flow 
wire, temperature and pressure sensor tripped coronary wire, or thrombolysis in 
myocardial infarction framecount and myocardial blush score(Arrebola-Moreno, et 
al. 2011). 
 
Table 1. Pharmacological stimuli that affect endothelial function 
 
 
Substance Result 
ACh infusion vasodilation 
paradoxical vasoconstriction in atherosclerosis based on smooth 
muscle cell contraction in the absence of NO release from 
endothelium 
Nitroglycerine vasodilation 
Substance P vasoconstriction 
Adenosine vasodilation 
Bradykinine vasoconstriction 
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Table 2.  Noninvasive techniques to assess endothelial function 
 
 
List of  commonly used markers of endothelial dysfunction. 
Endothelin-1 
Tissue plasminogen activator (TPA) 
Plasminogen activator inhibitor-1 (PAI-1) 
Soluble adhesion molecules 
Von Willebrandt factor (vWF) 
Asymmetric dimethylarginine (ADMA) 
Vascular endothelial growth factor (VEGF) 
Endothelial microparticles (EMPs) 
Endothelial progenitor cells (EPCs) 
Tech
nique 
Site Method Description Interpretation 
FMD Brachial 
artery 
Ultrasound A pneumatic cuff is placed 
distally to the arm, inflated and 
then released causing increase 
in flow “shear stress”,  then 
maximum vasodilation is 
measured with ultrasound. 
Measures the capacity of 
endothelial cells to produce 
NO, and smooth muscle cell 
capacity to relax, 
percentage of maximum 
change from the baseline 
diameter. 
 
PCA  Radial 
artery 
Photo- 
plethysmo-graphy/ 
tonometry 
Radial artery pulse waves are 
recorded. 
Oscillatory compliance is 
reduced in disease states. 
PAT  Finger 
 
Finger  
pneumatic plethysmo- 
graphic cuff 
Beat to beat blood flow volume 
is assessed. 
Post-ischemic blood flow is 
compared to baseline blood 
flow to assess the 
endothelial function. 
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The concentrations of these peptides increase when the endothelium is activated or 
damaged, and they are predictive at least to a certain extent of the risk, presence and 
the severity of vascular disease. Endothelial dysfunction may be assessed indirectly 
by plasma biomarkers that, although generally nonspecific, can provide an 
indication of cellular malfunction. Currently, in hypercholesterolemic or diabetic 
patients, the best indicators of EC dysfunction are showed to be the plasma NO 
metabolites (nitrites, nitrates), the increased concentration of vasoconstrictors (i.e. 
endothelin-1), von Willebrandt factor, and others(Simionescu. 2007). Various cell 
types release small membrane vesicles called microparticles (MP) on their activation, 
as well as during the process of apoptosis. The properties and roles of MP generated 
in different contexts are both diverse and are determined by their parent cell and the 
pathway of their generation which affects their content. MPs have been reported to 
be involved in multiple cellular functions, including immunomodulation, 
inflammation, coagulation, and intercellular communication(Shai and Varon. 2011). 
Investigations of MP could elucidate new cellular communication pathways and 
may lead to a better understanding of the underlying pathophysiological processes. 
From a clinical point of view, MP may serve as biomarkers for disease and may be 
found useful for developing novel therapeutic strategies targeting angiogenesis-
related conditions(Shai and Varon. 2011). 
2.2.1  High sensitive C-reactive protein 
Elevated high sensitive C-reactive protein (hsCRP) serum levels are indicative of a 
systemic inflammatory response and have been associated with a blunted systemic 
endothelial vasodilator function(Fichtlscherer, et al. 2000). In Framingham study, 
CRP correlated significantly to reactive hyperemia even after adjustment of 
traditional cardiovascular risk factors, but not to flow mediated vasodilation. It was 
concluded that inflammation had no attributable effects on endothelial function 
beyond traditional risk factors(Vita, et al. 2004).  
Järvisalo et al. showed that children with higher levels of serum ultrasensitive C-
reactive protein (≥0.1 to ≤0.7 and >0.7 mg/liter) demonstrated lower flow-mediated 
vasodilation than children with ultrasensitive CRP levels that were under the 
detection limit (less than 0.1 mg/l) (P = 0.015 for trend). The level of CRP remained a 
significant independent predictor for brachial artery flow-mediated vasodilation in 
multivariate analysis(Järvisalo, et al. 2002). 
2.2.2 Proinflammatory cytokines tumor necrosis factor-α and interleukin-6 
Tumor necrosis factor-α (TNF-α) is a multifunctional proinflammatory cytokine that 
belongs to the tumor necrosis factor superfamily. This cytokine is mainly secreted by 
macrophages. It can bind to and thus functions through its receptors 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the 
regulation of a wide spectrum of biological processes including cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation. It has been implicated 
in a variety of diseases, including autoimmune diseases, insulin resistance, and 
cancer. Knockout studies in mice also indicated that TNF-α has a neuroprotective 
function(Chudek and Wiecek. 2006, Gu, et al.). 
Interleukin-6 (IL-6) is a cytokine that functions in inflammation and the 
maturation of B cells. In addition, it has been shown to be an endogenous pyrogen 
capable of inducing fever in subjects with autoimmune diseases or infections. The 
protein is primarily produced at sites of acute and chronic inflammation, where it is 
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secreted into the serum and induces a transcriptional inflammatory response 
through the interleukin-6 receptor.  IL-6 is implicated in a wide variety of 
inflammation-associated disease states, including susceptibility to diabetes mellitus 
and systemic juvenile rheumatoid arthritis(Gu, et al.). 
Pro-inflammatory cytokines (TNF-α and IL-1β alone but not IL-6) induce transient 
and reversible endothelial dysfunction and cyclooxygenase activity may contribute 
to the genesis of the effect(Bhagat, et al. 1997). 
2.2.3 Asymmetric dimethylarginine 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide 
synthase (NOS) since it can compete with the binding of the natural substrate L-
arginine(Leone, et al. 1992). The pathway of the synthesis and elimination of ADMA 
is presented in the figure 3. 
 
Figure 3. Biochemical pathways for the generation, elimination and degradation of 
ADMA. ADMA derives from methylation of arginine residues in proteins. The reaction 
is catalyzed by protein arginine N-methyltransferases (PRMT). Hydrolysis of the 
methylated proteins releases ADMA, which competitively inhibits NOS. Renal 
excretion accounts for only 20% of ADMA elimination. The primary route of 
elimination (80%) is ADMA metabolism through the enzyme 
dimethylargininedimethylaminohydrolase (DDAH). DDAH hydrolyzes ADMA to form 
dimethylamine and L-citrulline. Generation of ADMA can be increased by shear 
stress, oxidized LDL and lysophosphatidylcholine (LPC). Many cardiovascular risk 
factor like cholesterol (oxLDL), homocysteine, hyperglycemia, cytomegalovirus (CMV) 
infection and cigarette smoke decrease DDAH activity and thereby increase ADMA. 
IL-1β and estrogen have been shown to increase DDAH activity and to lower plasma 
ADMA. With permission from(Kielstein et al. 2007). 
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ADMA increases vascular resistance and blood pressure in humans. ADMA is a 
strong and independent risk factor for mortality and cardiovascular events, both in 
the general population and in patients at different stages of chronic kidney 
disease(Jourde-Chiche, et al. 2011). Elevated plasma ADMA concentrations are 
known to be associated with decreased brachial FMD responses in healthy 
adults(Juonala, et al. 2007). However, in a recent study among 289 patients with 
coronary artery disease, no correlation was detected between plasma ADMA 
concentration and coronary response to acetylcholine, adenosine, or 
nitroglycerin(Maas, et al. 2007) The associations between FMD and methylarginines 
have been  rather weak and this may explain why the relation has not been detected 
in all studies. Pregnancy related changes in ADMA concentrations are discussed in 
the chapter  “Endothelium and regulation of vascular tone in preeclampsia”. 
2.3 FLOW MEDIATED DILATION 
 
Flow mediated dilation (FMD) is a term used to describe any vasodilation of an 
artery following an increase in luminal blood flow and internal-wall shear stress 
(Fig. 4). However, the term has conventionally come to describe subtle variations to 
the technique introduced by Celermajer, Deanfield, and colleagues in the Lancet in 
1992(Celermajer, et al. 1992). Today FMD is now the most commonly used 
noninvasive assessment of vascular endothelial function in humans. 
FMD refers to the assessment of peripheral conduit artery diameter following a 
period of distal limb ischemia by ultrasound. Nobel prize-winning experiments by 
Furchgott established that the endothelium produces a labile vasodilator 
substance(Furchgott and Zawadzki. 1980). Subsequently it was discovered that in 
response to flow, the endothelium had released a substance that possessed all of the 
characteristics of Furchgott's endothelium-derived relaxing factor; it was later 
identified as nitric oxide (NO)(Moncada, et al. 1988). The FMD technique has 
increasingly been applied in physiological studies to examine the mechanisms that 
alter vascular function and CVD risk (e.g., exercise training, smoking, 
hypercholesterolemia, hypertension)(Thijssen, et al. 2011). The FMD test represents 
an important way to improve our physiological insights and understanding of 
mechanisms that alter endothelial and vascular function. However, it is clear that 
minor changes in the methodological approach can critically impact on the nature 
and magnitude of the FMD response(Thijssen, et al. 2011). Since it is non-invasive, 
this method has been applied widely in asymptomatic subject groups, including 
children and young adults(Järvisalo, et al. 2006) and it also is suitable for pregnant 
women. The method has even been used in large population-based studies involving 
thousands of study subjects(Juonala, et al. 2004). 
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Figure 4.  The genesis of FMD, in response to different changes in shear stress. * 
Very short-term changes; ** changes taking place over slightly longer periods 
(minutes); *** changes taking place over a longer time (many minutes or hours). 
PGI2 prostacyclin; EDHF endothelium-derived hyperpolarizing factor; Kc calcium-
activated potassium channel. With permission from(Moens, et al. 2005). 
2.3.1  Limitations and weaknesses of flow mediated vasodilation 
The technical and methodological limitations of FMD are listed below(Inaba, et al. 
2010). In addition, there is extensive variability between studies with respect to the 
protocols applied, methods of analysis, and interpretation of results. Guidelines for 
the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of 
the brachial artery have been established(Corretti, et al. 2002) This technique is 
considered to be particularly well suited for study of the earliest stages of 
atherosclerosis in children and young adults, thus providing maximal opportunities 
for implementing prevention measures(Corretti, et al. 2002). 
 
Limitations of FMD 
1. Methodologies used for the measurement of FMD are not standardized between various vascular 
laboratories and thus there are no universal cut-off values for FMD, making it difficult to compare 
the results 
2. Due to the physiological fluctuations, there is a large intraindividual variation in intersession 
FMD 
3. A high-quality ultrasound device is necessary, those devices are expensive and demanding to 
use 
 
There is a wide interindividual variation in mean FMD so the accurate comparison 
of individual FMD data is somewhat troublesome. Figure 5 presents the FMD% 
values of 157 women in pregnancy by gestational weeks. 
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Figure 5. Flow mediated dilation of the brachial artery with gestation. Individual 
values and regression lines of the mean, 95th and 5 th centiles. Vertical line stands 
for 95th, mean and 5th percentiles for 19 nonpregnant controls. With permission from 
(Savvidou, et al. 2000). 
 
2.3.2 Clinical use of flow mediated vasodilation 
Brachial artery flow mediated vasodilation is mainly used for studying populations, 
but FMD is not merely a laboratory curiosity, it also has clinical applications. The 
most common finding is that reduced FMD is associated with various cardiovascular 
risk factors. It has been claimed that FMD strongly predicts cardiovascular events in 
patients with established cardiovascular disease(Thijssen, et al. 2011). Over a 6-year 
follow-up, FMD was reported to correlate with the progression of preclinical carotid 
artery disease, showing a closer relationship with disease progression than 
conventional risk factors(Halcox, et al. 2009). Impaired FMD has been reported to 
predict short and long term cardiovascular events(Gokce, et al. 2003)(Karatzis, et al. 
2006)(Schachinger, et al. 2000). Impaired flow mediated vasodilation in the brachial 
artery (5.8 % ± 3.4 vs. 9.0 % ± 4.8, p = 0.005) four weeks after percutaneous coronary 
intervention independently predicted the risk of clinical restenosis(Munk, et al. 
2011). 
 
2.4 THE FACTORS THAT ALTER ENDOTHELIAL FUNCTION 
 
In addition to specific medical illnesses FMD can be influenced by recent aerobic or 
resistance exercise(Black, et al. September 2009)(Dawson, et al. 2008) (Harris, et al. 
2008), dietary intake, caffeine(Papamichael, et al. 2005) and alcohol 
ingestion(Hijmering, et al. 2007), and use of supplements or medications(Magen, et 
al. 2005)(Harris, et al. 2009), smoking, menstrual phase and repeated 
measurements(Harris, et al. 2010). Endothelial dysfunction referred initially to 
structural changes in endothelium, such as those seen in atherosclerosis, but 
nowadays this term is used to describe the loss of the endothelium’s ability to 
regulate vascular resistance.  
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2.4.1 Inflammation 
Almost every stimulus evoking to a systemic inflammatory response i.e. severe 
infection, trauma, excessive tissue breakdown, solid tumours, leukaemia, pregnancy 
associated complications such as hypertensive disorders and GDM, liver failure, and 
toxicological or immunological responses and activation of the coagulation system 
can be associated with endothelial damage(Paulus, et al. 2011). Inflammatory 
processes associated with endothelial damage, with a special focus on 
arteriosclerosis, are presented in figure 6. 
 
Figure 6. Inflammatory processes that are involved in arteriosclerosis. Low-density 
lipoprotein (LDL) infiltrates the artery wall and undergoes modification by oxidation. 
The modified LDL particles then induce the expression of adhesion molecules, 
including vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1). Monocytes migrate into the vessel wall and differentiate into 
macrophages. After migration through the endothelial layer, the monocytes 
differentiate into macrophages and scavenge the oxidized low density lipoprotein 
(oxLDL) from the vessel wall, resulting in foam cell formation. Stimulation of toll-like 
receptors (TLRs) of macrophages results in the release of several proinflammatory 
cytokines, such as TNF-α, IL-1β and IL-6. T cells become activated during this time 
and produce other mediators such as interferon (INF-γ), which further amplifies the 
inflammatory response and contributes to atherogenesis. The activation of TLRs also 
induces expression of matrix-degrading matrix metalloproteinases (MMPs), which 
probably play a role in weakening the fibrous cap and promoting plaque vulnerability. 
With permission from(Gu, et al. 2012). 
 
Cardiovascular risk factors, such as smoking, hypercholesterolemia, and elevated 
blood pressure give rise to a variety of noxious stimuli that elicit secretion of both 
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leukocyte soluble adhesion molecules, which facilitate the attachment of monocytes 
to endothelial cells, and chemotactic factors, which encourage the migration of 
monocytes into the subintimal space. The transformation of monocytes into 
macrophages and the uptake of cholesterol lipoproteins are thought to initiate the 
fatty streak. Further injurious stimuli may continue the attraction and accumulation 
of macrophages, mast cells, and activated T cells within the growing atherosclerotic 
lesion, and secretion of metalloproteinases and other connective tissue enzymes by 
activated macrophages may break down collagen, weakening the cap and making it 
prone to rupture. Thus, virtually every step in atherogenesis is believed to involve 
cytokines, other bioactive molecules, and cells that are characteristically associated 
with inflammation(Pearson, et al. 2003). 
2.4.2 Hypertension 
An association between endothelial dysfunction and hypertension is well 
established. Data from the Framingham offspring cohort suggest that the severity of 
hypertension is positively associated with the degree of impairment of endothelial 
function(Benjamin, et al 2004). 
Endothelium mediated vascular relaxation following acetylcholine infusion is 
reduced in essential hypertension compared to normotensive controls(Panza, et al. 
1990). The pathophysiology of hypertension involves a complex interaction of 
multiple vascular effectors including the activation of the sympathetic nervous 
system, of the renin–angiotensin–aldosterone system and of the inflammatory 
mediators. Subsequently vasoconstriction and inflammation ensue, leading to vessel 
wall remodeling and finally, to the formation of atherosclerotic lesions as the 
hallmark of advanced disease. Oxidative stress and endothelial dysfunction are 
consistently observed in hypertensive subjects, but emerging evidence suggests that 
they also have a causal role in the molecular processes leading to 
hypertension(Schulz, et al. 2011). 
The discovery of vascular receptors that control vessel tone and neurohumoral 
mediators in hypertension has led to the development of modern antihypertensive 
drugs such as beta-blockers, angiotensin converting enzyme inhibitors, AT-1 
receptor blockers or calcium channel blockers. Although the pathophysiology of 
hypertension is extremely complex and multifactorial, and the role of factors such as 
endothelin, cyclooxygenase-dependent vasoconstrictors and endothelium-derived 
hyperpolarizing factor needs to be acknowledged, numerous experimental animal 
studies indicate that this condition is associated with an increased formation of 
reactive oxygen species (ROS) from all layers of the vascular wall(Schulz, et al. 2011). 
2.4.3 Renal disease 
Endothelial dysfunction is a hallmark of chronic kidney disease (CKD). Patients with 
CKD show endothelial dysfunction resulting from increased endothelial injury and 
decreased endothelial repair. Patients with CKD are known to display impaired 
endothelium-dependent vasodilation, elevated soluble biomarkers of endothelial 
dysfunction, and increased oxidative stress(Jourde-Chiche, et al. 2011). Several 
uremic toxins, mostly protein-bound, have been associated with specific endothelial 
toxicity: ADMA, homocysteine, advanced glycation end products (AGEs), and more 
recently, p-cresyl sulfate and indoxyl sulfate. These toxins, all poorly removed by 
hemodialysis therapies, share mechanisms of endothelial toxicity: they promote pro-
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oxidant and pro-inflammatory responses and inhibit endothelial repair(Jourde-
Chiche, et al. 2011).  
2.4.4 Hyperlipidemia 
Increased plasma levels of low density lipoprotein (LDL) particles damage the 
endothelium favouring LDL entry and accumulation within the arterial wall. 
Oxidized low-density lipoproteins may be one of several factors that contribute to 
loss of smooth muscle cells through apoptosis in the atherosclerotic plaque 
cap(Pearson, et al. 2003). Elevated high density lipoprotein (HDL) levels reduce the 
risk of coronary events regardless of LDL levels. It is currently believed that most of 
the atheroprotective effects of HDLs stem from their capacity to remove cholesterol 
from the vasculature, and to deliver it to the liver for disposal in a process 
commonly referred to as reverse cholesterol transport (RCT)(Badimon, et al. 2011). 
There is no consensus as to whether flow-mediated vasodilation is correlated with 
LDL cholesterol.  
2.4.5  Obesity 
Adipose tissue releases a large number of bioactive mediators that influence not only 
body weight homeostasis but also insulin resistance, which is the core feature of type 
2 diabetes, as well as alterations in lipids, blood pressure, coagulation, fibrinolysis 
and inflammation, leading to endothelial dysfunction and atherosclerosis(Van Gaal, 
et al. 2006). Obesity increases the risk of cardiovascular disease and premature 
death(Yusuf, et al. 2004). The accumulation of abdominal fat independently 
increases cardiovascular risk. In The Nurses' Health Study the waist-to-hip ratio 
reflects abdominal fat in predicting type 2 diabetes, stroke, myocardial infarction 
and cardiovascular mortality in middle-aged individuals(Rexrode, et al. 1998). 
Obesity has been linked to impaired coronary and peripheral endothelial 
function(Benjamin, et al. 2004). In The Cardiovascular Risk in Young Finns Study, an 
opposite finding was done - increased BMI was found to correlate positively to 
FMD(Juonala, et al. 2004). An increase in body size within the nonobese range in a 
population of healthy young adults seems to be associated with physiological 
changes that lead to enhanced FMD responses and overcomes the opposing 
influences of the larger vessel size and increased oxidative stress associated with 
higher BMIs(Juonala, et al. 2004). 
2.4.6 Metabolic syndrome 
Metabolic syndrome is characterized by atherogenic dyslipidemia (low HDL and 
high triglycerides levels), elevated blood pressure, elevated plasma glucose levels, a 
prothrombotic state, and a proinflammatory state(Cho. 2011). The proinflammatory 
state is a result of an increase in adipocyte mass and macrophage infiltration in fat 
tissue and other organs. The presence of elevated blood pressure, elevated blood 
glucose and serum free fatty acid levels, hyperinsulinemia, and insulin resistance 
lead to endothelial dysfunction in skeletal muscle, liver, and impairments in 
microcirculations(Vykoukal, et al. 2011). 
2.4.7 Diabetes 
Both type 1 and type 2 DM patients suffer an increased risk for cardiovascular 
morbidity and mortality. Patients with diabetes have twice the risk of incident 
myocardial infarction and stroke as that of the general population(Buse et al., 2007). 
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As many as 80% of patients with type 2 DM will develop and possibly die of 
macrovascular disease(Buse et al., 2007). The relation between diabetic micro- and 
macroangiopathy and endothelial dysfunction is complex and is still a subject of 
extensive research. In addition to the metabolic actions of insulin in coordinating 
glucose homeostasis, a complete biochemical signaling pathway linking the insulin 
receptor to activation of eNOS in vascular endothelium has recently been 
elucidated(Yu, et al. 2011). The increased and accelerated rate of apoptosis of 
endothelial cells is probably a crucial factor in diabetic co-morbidity. There are many 
pathways involved in activating endothelial cell apoptosis and all of these pathways 
can be activated in multiple ways. A common mechanism triggering endothelial 
dysfunction and endothelial cell apoptosis is oxidative stress(Giugliano, et al. 
1996)(Kuroki, et al. 2003). Hyperglycemia alone accelerates the development and 
progression of atherosclerotic lesions and the rapid formation of EC-derived foam 
cells(Simionescu, et al. 1996). In pregnancy type 1 diabetes has been found to 
associate with impaired endothelial function( Savvidou, et al. 2002). 
2.4.8 Alcohol 
Low concentrations of alcohol induce increased release of NO from the endothelium 
due to activation and expression of NO synthase (NOS). In contrast, administration 
of high concentrations of alcohol or its chronic ingestion impairs endothelial function 
in association with reduced NO bioavailability. The endogenous NOS inhibitor 
asymmetric dimethylarginine may be involved in the decreased synthesis of 
NO(Toda and Ayajiki. 2010). 
2.4.9 Oxidative stress 
Reactive oxygen species (ROS) are a family of molecules including molecular oxygen 
and its derivatives produced in all aerobic cells(Cai and Harrison. 2000). Excessive 
production of ROS, outstripping endogenous antioxidant defense mechanisms, has 
been implicated in processes where these reactive radicals oxidize biological 
macromolecules, such as DNA, protein, carbohydrates, and lipids. This condition 
has commonly been referred to as oxidative stress. There is evidence that ROS 
induce endothelial dysfunction by affecting eNOS expression or by inactivation of 
NO through the formation of lipid peroxidation products and peroxynitrite radicals 
that disturb the EC membrane directly(Cai and Harrison. 2000) 
2.4.10 Estrogens 
Estrogens, and in particular 17beta-estradiol (E2), play a pivotal role in sexual 
development and reproduction. Both acetylcholine-induced and flow-dependent 
vasodilation are preserved or potentiated by estrogen treatment in both animal 
models and humans(Miller et al. 2008). E2 increases the endothelial production of 
nitric oxide and prostacyclin and prevents early atheroma through endothelial-
mediated mechanisms. Furthermore E2 potentiates the ability of several 
subpopulations of the circulating or resident immune cells to produce 
proinflammatory cytokines. E2 also promotes endothelial healing, and it is involved 
in angiogenesis(Arnal, et al. 2010). The actions of estrogens are essentially mediated 
by two molecular targets: estrogen receptor-alpha (ERα) and ERbeta. ERα appears to 
mediate most of the actions of E2 on the endothelium and the immune system, 
Arnal, et al. 2009). ERα activation function-1 (AF-1) is not required for the 
vasculoprotective actions of E2, whereas it is necessary for the effects on its 
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reproductive targets. Selective estrogen receptor modulators (SERMs) stimulating 
ERα, with minimal activation of ERα AF-1, are used in order to achieve beneficial 
vascular actions, while minimizing the sexual effects(Arnal, et al. 2009). The types of 
receptor isoforms vary from tissue to tissue and from species to species. This may 
account for considerable functional diversity, but this emerging field has not yet 
matured enough to give clear insights into implications for the actions of estrogen on 
a particular organ system, such as the vasculature(Miller and Duckles. 2008). Thus 
the clinical use of estrogen in preventing or treating cardiovascular disease is 
controversial. 
  
2.5 ENDOTHELIUM IN PREGNANCY 
2.5.1  Endothelium and regulation of vascular tone in normal pregnancy 
Normal pregnancy is characterized by vasodilation resulting in reduction of 
peripheral vascular resistance. Blood pressure begins to decrease early in the first 
trimester and reaches its nadir by 20 to 24 weeks' gestation. The physiological 
changes are not completely understood, but the human chorionic gonadotropin–
induced increased production of relaxin by the corpus luteum may facilitate 
vasodilation in normal pregnancy. Relaxin up-regulates vascular gelatinase activity 
thereby contributing to vasodilation and reduced myogenic reactivity of small 
arteries through activation of the endothelial endothelin B receptor–nitric oxide 
pathway(Boeldt, et al. 2011). The amount of NO produced by endothelial NO 
synthase (eNOS) is determined by the maximum capacity of the cell (eNOS 
expression levels), the eNOS phosphorylation state, and the intracellular [Ca2+]i 
concentration in response to circulating hormones or physical forces(Boeldt, et al. 
2011). In early pregnancy, the magnitude of the endothelium-dependent FMD of the 
brachial artery is determined in part by carriage of the endothelial nitric oxide 
synthase gene polymorphism Asp298 variant(Savvidou, et al. 2001). Angiogenic 
factors such as vascular endothelial growth factor (VEGF) also may have an 
important function in the increased production of NO and prostacyclin in pregnancy 
via pathways involving phospholipase C, mitogen-activated protein kinase, and 
protein kinase C. The balance between vasodilatory (NO, prostacyclin) and 
vasoconstrictive (thromboxane A2, endothelin) substances, and in parallel the 
balance between angiogenic and anti-angiogenic factors, are speculated to be 
important determinants of blood pressure in pregnancy(Cornelis, et al. 2011).  
In pregnancy, vascular nitric oxide (NO) production is increased in the systemic 
and more so in the uterine vasculature, thereby supporting maximal perfusion of the 
uterus(Boeldt, et al. 2011). Increased activity of the NO vasodilatory mechanism 
occurs in the maternal systemic vasculature in general and this is even more 
pronounced in the uterine vasculature. Several studies have described 
improvements in endothelial function in terms of brachial artery FMD during 
normal pregnancy with some alterations between the three trimesters(Dorup, et al. 
1999) (Savvidou, et al. 2000) (Faber-Swensson, et al. 2004) (Seeliger, et al. 2011). In the 
first study 71 normal pregnant women were compared to 37 controls and FMD% 
was increased in all three trimesters (9.1 and 9.1. and 10.6%) compared to 
nonpregnant controls who had mean FMD% of 7.2%(Dorup, et al. 1999). The largest 
of these studies consisted of a sample of 157 pregnant women who were investigated 
at gestational weeks 10-40 and compared to 19 non-pregnant controls. In final 
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analysis they took pregnancies from 10 to 30 weeks, because FMD% decreased later 
in pregnancy. Mean FMD% in pregnancy was 8.84 ± 3.18% and in nonpregnant 
controls 6.42 ± 2.45% (P=0.002) (Savvidou, et al. 2000). In 74 twin pregnancies the 
flow mediated vasodilation was comparable to 98 singleton pregnancies (9.61 ± 4.36 
vs. 8.84 ± 3.18%) during the weeks 11-30 (Savvidou, et al. 2001). In a longitudinal 
study increase of FMD% did not reach significance in pregnancy up to 32 weeks, but 
decreased after 36 weeks significantly(Quinton AE, et al. 2007). Another longitudinal 
study completed in all the three trimesters and postpartum showed that FMD% 
increased from the first trimester to the second trimester (8.0 ± 5.58 vs. 15.2 ± 5.19, 
P=0.003) and attenuated again to the third trimester (9.15 ± 3.61%, P=0.004 between 
the second and third trimesters) and postpartum values were comparable to first 
trimester(Seeliger, et al. 2011). 
2.5.2  Endothelium and regulation of vascular tone in  preeclampsia 
Although preeclampsia appears to originate in the placenta, the tissue affected most 
is the maternal endothelium. The clinical manifestations of preeclampsia reflect 
widespread endothelial dysfunction, with vasoconstriction and end-organ ischemia. 
The hypertension is characterized by peripheral vasoconstriction and decreased 
arterial compliance(Powe, et al. 2011).  The proteinuria of preeclampsia is associated 
with a pathognomonic renal lesion known as glomerular endotheliosis, in which the 
endothelial cells of the glomerulus become swollen and endothelial fenestrations are 
lost(Powe, et al. 2011). 
Exposure of endothelial cells to serum from women with preeclampsia results in 
endothelial dysfunction. It has been hypothesized that circulating factors, probably 
originating in the placenta, are responsible for the manifestations of the 
disease(Boeldt, et al. 2011). Dozens of serum markers of endothelial activation and 
endothelial dysfunction are known to be deranged in women with preeclampsia, 
including von Willebrand antigen, cellular fibronectin, soluble tissue factor, soluble 
E-selectin, platelet-derived growth factor, and endothelin(Maynard, et al. 2008). 
Women who developed pre-eclampsia or intra uterine growth restriction (IUGR) 
later in pregnancy had significantly lower FMD at gestational weeks 23-25 than 
those women who had normal outcome (3.6 vs. 6.17 vs. 8.6%, p<0.0001)(Savvidou, et 
al. 2003). Irrespective of pregnancy outcome, women with evidence of impaired 
placental perfusion had significantly higher levels of ADMA than women with 
normal Doppler waveforms (2.4 μmol/L [IQR 1.97–3.14] vs. 0.81 μmol/L [0.49–1.08]; 
p<0.0001). There was a strong inverse correlation between ADMA levels and flow-
mediated dilation but only in the group of women who eventually developed pre-
eclampsia (r=−0.8, p=0.005)(Savvidou, et al. 2003).  In the placenta it has been 
reported that DDAH expression and activity in pre-eclampsia were almost 
undetectable and ADMA plasma levels were higher in women with pre-eclampsia 
compared to normal pregnant women(Anderssohn, et al. 2012) 
Endothelial dysfunction in preeclampsia may be more pronounced in 
uteroplacental vasculature than in general vasculature and failure in shear stress 
mediated vasodilation in myometrial arteries might contribute to impaired 
uteroplacental blood flow(Kublickiene, et al. 2000)(Nisell, et al. 1991)(Acharya et al. 
2009). 
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2.5.3 Endothelial function in women with previous preeclampsia 
Flow mediated vasodilation was found to be significantly reduced in women with 
previous early-onset preeclampsia and IUGR compared with women with previous 
late-onset preeclampsia and control subjects (3.2±2.7% and 2.1±1.2% versus 7.9±3.8% 
and 9.1±3.5%, respectively; P<0.0001) 6 to 24 months postpartum(Yinon, et al. 2010). 
Endothelium independent vasodilation was similar among all groups. In contrast, 
women with a history of late-onset preeclampsia exhibited normal FMD i.e. similar 
to control subjects. Using pulse-wave analysis, it was demonstrated that arterial 
stiffness was increased in both women with a history of early preeclampsia and 
women with previous normotensive IUGR relative to women with previous late-
onset preeclampsia and healthy control subjects(Yinon, et al. 2010) In a recently 
published study no evidence of endothelial dysfunction (measured with strain 
gauge plethysmography) nor sympathetic overactivity was detected in the 
postpartum state in women with a history of preeclampsia or gestational 
hypertension(Mangos, et al. 2012). 
In a Swedish study with small population (N=18) the mean value of FMD 
measured one year after pregnancy was remarkably lower in women with history of 
preeclampsia than in control women (2.5 ± 2.9% vs. 10.3 ± 2.0%)(Hamad, et al. 2007). 
Lampinen et al. described impairement in endothelium independent and -dependent 
vascular dilatory capacity in women with a history of moderate/severe preeclampsia 
after 5-6 years of pregnancy(Lampinen, et al. 2006). In their study vasodilatory 
function was assessed with venous occlusion plethysmography with the change in 
flow being measured in resistance vessels of the forearm resulting from vasodilation 
after intra-arterial infusions of vasodilatory substances(Lampinen, et al. 2006).  
2.5.4 Preeclampsia and subsequent risk for hypertension and cardiovascular 
disease 
Women with two episodes of preeclampsia were approximately 10 times more likely 
to be using antihypertensive medication at follow-up (adjusted odds ratio, 11.6, 95% 
CI 7.1-26.3), and in women with gestational hypertension in three consecutive 
pregnancies, systolic pressure was on average 27 mmHg (95% CI 18-37 mm Hg) 
higher, and diastolic pressure was 12 mmHg (95% CI 5-19 mmHg) higher, compared 
with women without a history of gestational hypertensive disorders(Magnussen, et 
al. 2009) According to another study women with a history of preeclampsia had 
double the risk of hypertension and coronary artery disease compared with control 
subjects(Andersgaard, et al. 2012). They had carotid plaques more often, had larger 
total carotid plaque area and thicker intima-media layer compared with control 
subjects. A family history of CVD was more common among these women, which 
suggested that the familial risk may be associated with underlying genetic 
predisposition towards vascular dysfunction or other related factors (such as familial 
food habits, life style) (Andersgaard, et al. 2012). In a large meta-analysis, it was 
found that after preeclampsia women displayed an increased risk of vascular 
disease. The relative risks (95% confidence intervals) for hypertension were 3.70 (2.70 
to 5.05) after 14.1 years weighted mean follow-up, for ischemic heart disease 2.16 
(1.86 to 2.52) after 11.7 years, for stroke 1.81 (1.45 to 2.27) after 10.4 years, and for 
venous thromboembolism 1.79 (1.37 to 2.33) after 4.7 years. No increase in risk of any 
cancer was found (0.96, 0.73 to 1.27), including breast cancer (1.04, 0.78 to 1.39) 17 
years after pre-eclampsia. Overall mortality after preeclampsia was increased: 1.49 
(1.05 to 2.14) after 14.5 years(Bellamy, et al. 2007). In a Finnish study, it was found 
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that a history of preeclampsia was an independent risk factor for subsequent 
coronary artery disease among other well known risk factors (hypertension, 
diabetes, hypercholesterolemia, advanced age, smoking), and even after adjusting 
for other risk factors  (OR 4.8 (1.2–19)) (Haukkamaa, et al. 2004). 
Although the increased risk for hypertension and cardiovascular disease seems 
evident, the mechanisms behind this phenomenon are somewhat unclear. A 
permanent endothelial dysfunction and metabolic risk factors have been suggested 
to provoke the risk. In the Avon Longitudinal Study of Parents and Children 
(ALSPAC), which is a prospective population-based birth cohort study  with 14,541 
pregnancies resident in Avon, UK both gestational hypertension and preeclampsia 
were associated with a greater number of cardiovascular risk factors: BMI, waist 
circumference, systolic and diastolic blood pressure values, insulin, proinsulin, 
triglycerides, and HDL cholesterol. Mothers of small for gestational age babies had 
higher systolic and diastolic blood pressure compared to mothers with appropriate 
for gestational age babies, as did mothers who delivered before term(Fraser, et al. 
2012). In other studies, women with previous preeclampsia have exhibited features 
of metabolic syndrome which were presumably present already before pregnancy, 
predisposing them to hypertensive disorders of pregnancy and a later 
cardiovascular risk.(Mangos, et al. 2012) No difference in insulin sensitivity in 
women with previous preeclampsia as compared with the control women was 
found(Mangos, et al. 2012) and similar results were reported in the study by  
Lampinen et al. Insulin sensitivity was found to correlate with vascular dilatory 
function in women with previous preeclampsia, suggesting that there was a 
relationship between the metabolic and vascular functions(Lampinen, et al. 2008). 
2.5.5 Gestational diabetes and endothelial function 
Abnormal carbohydrate metabolism associated with endothelial dysfunction during 
pregnancy. In the last trimester of pregnancy, FMD% was 4.1 % in GDM group vs. 
10.9 % in control group and a strong negative relation was found between FMD and 
glucose area under curve (AUC)(Paradisi, et al. 2002). In addition impaired 
endothelium dependent vasodilation has been found in euglycemic women with 
previous GDM(Anastasiou, et al. 1998). Endothelial dysfunction in diabetes is 
thought to be mainly due to hyperglycemia(Williams, et al. 1998) and its adverse 
effects on endothelium have been discussed earlier. 
In the ALSPAC study, it was found that pre-gestational diabetes, GDM and 
glucosuria were all associated with higher glucose concentrations eighteen years 
after pregnancy even when controlling for potential confounders including pre-
pregnancy BMI(Fraser, et al. 2012). Pregnancy diabetes was associated with higher 
glucose levels, GDM and glucosuria were also associated with higher insulin and 
proinsulin, and furthermore glucosuria was associated with higher triglyceride 
levels(Fraser, et al. 2012). Similarly, mothers to large for gestational age (LGA) babies 
had higher glucose levels than mothers of AGA babies - in line with the established 
linear association between maternal glycemic status and the risk of delivering an 
LGA infant(Fraser, et al. 2012). 
2.5.6 Gestational diabetes and hypertensive disorder in pregnancy and future 
cardiovascular risk 
There are many women that experience more than one pregnancy complication. 
There are few studies about how the risks accumulate in these women. Hypertension 
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in pregnancy and pregnancy diabetes are independently associated with an 
increased calculated 10 year CVD risk(Fraser, et al. 2012). Preeclampsia may be a 
better predictor of future CVD since it was associated with a wider range of 
cardiovascular risk factors(Fraser, et al. 2012). Pregnant mothers with chronic 
hypertension and GDM are more insulin resistant than those with GDM 
alone(Caruso, et al. 1999). Blood pressure is a stronger predictor of insulin resistance 
than adiposity in a population of pregnant women with normal and abnormal 
carbohydrate metabolism(Caruso, et al. 1999). After delivery, women with GDM 
often have an increased risk for developing metabolic syndrome and they present 
with early markers of vascular disease such as endothelial dysfunction and increased 
intima-media thickness of carotid arteries(Bo, et al. 2007, Kaaja and Ronnemaa. 2008) 
Thus, pregnancy may act as a “stress test”, revealing a woman’s predisposition to 
type 2 diabetes and it can be viewed as an opportunity for providing focused 
prevention of important chronic diseases.(Kaaja and Ronnemaa. 2008). 
2.5.7 Complications in pregnancy and vascular health of the offspring 
Coronary heart disease is believed to result from the unhealthy lifestyles of 
westernized adults in conjunction with a contribution from genetic inheritance. 
Geographical studies provided the first clue that the disease originates during intra-
uterine development. In animal studies it has been found that if adult rat offspring 
were exposed to prenatal hypoxia then their flow-mediated vasodilation was 
impaired (Morton, et al. 2011).  According to Barker’s studies, small birth weight 
correlated to cardiovascular disease(Barker and Osmond. 1986). Impaired fetal 
growth and prematurity were associated with impaired endothelial function and 
elevated preclinical atherosclerosis in young adults, partly mediated by 
inflammation, blood pressure, and triglyceride levels(Skilton, et al. 2011). If the fetus 
is exposed to GDM then this will add an intrauterine environmental risk factor to an 
already increased genetic risk for the development of obesity and/or diabetes. 
Maternal nutritional status (under- or overnutrition) can also affect the vascular 
function in the offspring(Poston, 2011).  
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3 Aims of the study 
The overall aim of this study was to assess the endothelial function in normal and 
complicated pregnancies. Firstly we wanted to evaluate the normal range of FMD in 
women with uncomplicated pregnancies. Secondly, we hypothesized that in 
gestational diabetes and preeclampsia we would find endothelial dysfunction 
compared to normal pregnant women. Thridly, we wanted to investigate factors that 
alter the vascular tone during normal and complicated pregnancy. The individual 
aims were to determine 
 
1. FMD and lipid levels in pregnant vs. non-pregnant healthy women. 
 
2. FMD and the concentrations of asymmetric dimethylarginine (ADMA) in 
healthy pregnant vs. non-pregnant women. 
 
3. FMD and the levels of proinflammatory cytokines and hsCRP in normal 
pregnancy vs. non-pregnant healthy women and their association with FMD 
during pregnancy. 
 
4. the endothelial function and the concentrations of proinflammatory 
cytokines and hsCRP in normal vs. pre-eclamptic pregnancies and postpartum. 
 
5. FMD and levels of proinflammatory cytokines in gestational diabetes vs. 
normal pregnancy and postpartum period. 
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4 Material and methods 
4.1 PATIENTS IN STUDIES I-III 
 
The Cardiovascular Risk in Young Finns Study is an ongoing population-based 5-
centre follow-up study of atherosclerosis risk factors in Finnish children and 
adolescents. The first cross-sectional survey was conducted in 1980. The original 
sample size was 4,320 children and adolescents aged 3, 6, 9, 12, 15 and 18 years. The 
individuals were randomly chosen from the national register. There were 3,596 
participants who participated in 1980. We re-examined 2,283 of these individuals in 
2001 when they were aged 24–39 years. The loss of participants was 34%. Out of this 
sample, 62 of the participants were pregnant and in 57 cases there was complete data 
about endothelial function. There were 13 women (23%) in the first trimester (≤14 
weeks), 20 women (35%) in the second trimester (15–27 weeks) and 22 women (39%) 
in the third trimester (≥28 weeks); the gestational age data were not available for 2 
patients (3%). The mean gestational age was 23±9 weeks. For the present analysis we 
chose these 57 pregnant women and 62 non-pregnant women matched for age and 
smoking status. There were 25/62 oral contraceptive (OC) users in control group. 
 
 The parameters used in this thesis from the Cardiovascular Risk in Young Finns Study 
 
Weight, height, BMI 
Smoking 
Blood pressure 
Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides 
CRP, ADMA, TNF-α, IL-6 
Brachial artery flow-mediated dilation 
 
4.2 PATIENTS IN STUDIES IV-V 
 
A total of 110 women were recruited from Kuopio University Hospital maternity 
clinic for the Complicated Pregnancy study Group in the years 2003-2008. The 
subgroups and the number of women are presented in Table 7.  
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Table 3. Subgroups and number of women recruited in Kuopio University Hospital Maternity 
Clinic for The Complicated Pregnancy Study. 
 
Study group Pregnancy(N) After pregnancy (N) 
Normal 32 27 
Hypertensive 14 9 
Preeclampsia 12 7 
GDM (diet) 42 26 
GDM (insulin) 10 7 
 
Hypertension was defined as blood pressure ≥140/90 mmHg in two separate 
measurements 6 hours apart or 30/15 mmHg increase in blood pressure during 
pregnancy.  Preeclampsia was defined as hypertension and proteinuria ≥ 300 mg 
over 24 hours. If blood pressure was over 160/100 mmHg in two separate 
measurements or the patient had symptoms such as headache, labetalol medication 
was started.  At the time of FMD measurement 16/26 hypertensive patients had 
antihypertensive medication. 
Gestational diabetes was defined as an abnormal 2-h 75 g glucose test. In Finland 
screening for GDM is a selective risk-related procedure (only pregnant women with 
one or more risk factors for GDM are screened. Plasma venous values lower than 
4.8–11.2–9.9 mmol/l were considered normal (fasting–1 h–2 h) in 2003-2008. Of the 
GDM women, 91.7% had fasting glucose value higher than reference value, 27.7% 
had 1-h value and 4.3% had 2-h value higher than the reference value. If the mother 
had at least one value over the reference range, she was included to the GDM group 
and the diagnosis was confirmed with a blood glucose profile, measuring blood 
glucose every 4 h over 24 h. Women with GDM received dietary advice, regular 
blood glucose controls (at home, capillary plasma glucose levels 3 days/week), and 
insulin when necessary (fasting capillary plasma glucose levels repeatedly over 5.5 
mmol/l or postprandial over 7.8 mmol/l). 
 
4.3 METHODS 
4.3.1 Anthropometry and Physiology  
Height and weight were measured. Blood pressure was measured with a random 
zerosphygmomanometer (Hawksley & Sons Ltd, Lancin, UK) while the patient was 
seated after 5 min rest. Korotkoff’s fifth phase was used as the sign of diastolic blood 
pressure and first phase as the sign of systolic blood pressure. Readings to the 
nearest even number of millimetres of mercury were performed at least 3 times for 
each subject and the average of these measurements was used in the analysis in The 
Cardiovascular Risk in Young Finns Study and The Complicated Pregnancy Study. 
For the assessment of cardiac output, the maternal electrocardiography (ECG) 
(Rigel Multicare 302, Morden, Surrey, England) and non-invasive beat-to-beat 
arterial blood pressure (Finapres digital plethysmograph, Ohmeda Inc., Englewood, 
CO, USA) were recorded for 5 minutes at rest in the supine position during and after 
pregnancy. Continuous blood pressure recording was performed from the middle 
finger of the right hand. Stroke volume was assessed from the non-invasive blood 
pressure signal by using the arterial pulse contour method, which is modified from 
the model flow method. Cardiac output was calculated from the equation: cardiac 
output = heart rate x stroke volume. All recordings and data analyses were 
performed with an IBM PC-compatible microcomputer with commercial 
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WINACQ/WINCPRS acquisition electronics and software (Absolute Aliens Oy, 
Turku, Finland), which includes a sophisticated analysis program designed for 
research in cardiovascular physiology. 
In addition, in The Complicated Pregnancy Study, all subjects went through 
twenty-four-hour ambulatory ECG, ambulatory blood pressure recordings, 
autonomic nervous system assessment and body composition analysis by 
bioimpedance during and after pregnancy but the data were not used in this 
analysis.  
4.3.2 Blood samples 
In the Cardiovascular Risk in Young Finns Study venous blood samples were drawn 
from the right antecubital vein of recumbent subjects after an overnight fast. Fasting 
blood samples were drawn from each subject during pregnancy and three months 
postpartum in the Complicated Pregnancy Study. Venous blood samples were 
drawn from the right antecubital vein of recumbent subjects after a 12-hour 
overnight fast for the determination of serum hsCRP, TNF-α and IL-6 and serum 
lipids and lipoprotein concentrations. Serum was separated by centrifugation and 
samples were stored frozen (-70 °C) until analysis. 
4.3.2.1 Glucose 
In the Cardiovascular Risk in Young Finns Study glucose concentrations were 
analyzed enzymatically (Olympus Diagnostica GmbH, Hamburg, Germany). In the 
Complicated Pregnancy Study plasma glucose was determined by the hexokinase 
method (Konelab 60i Clinical Chemistry Analyzer, Thermo Electron Co., Finland). 
4.3.2.2 Lipid determinations 
Lipid determinations in the Cardiovascular Risk in Young Finns study were 
determined enzymatically (Olympus System Reagent; Olympus Diagnostica GmbH, 
Hamburg, Germany) in a clinical chemistry analyser (AU400; Olympus Optical Ltd, 
Mishima, Japan). HDL cholesterol was analysed after precipitation of very low 
density lipoprotein (VLDL) and low density lipoprotein (LDL) with dextrane 
sulphate 500 000. The concentration of LDL cholesterol was calculated using the 
Friedewald formula(Friedewald, et al. 1972). Subjects with triglycerides above 
4 mmol L−1 (n = 32) were excluded from this analysis(Juonala, et al. 2004). In the 
Complicated Pregnancy Study cholesterol and triglyceride levels were assayed by 
standard enzymatic photometric methods with Konelab 60i Clinical Chemistry 
Analyzer (Thermo Electron Co, Finland). 
4.3.2.3 L-Arginine and asymmetric dimethylarginine analysis 
Serum L-arginine, ADMA and symmetric dimethylarginine (SDMA) levels were 
determined by a high performance liquid chromatography (HPLC) method with the 
precolumn ortho-phthaldialdehyde (OPA) derivatization described earlier 
(Valtonen, et al. 2005). Prior to analysis, the standards, controls and samples were 
extracted on Waters Oasis MCX solid phase extraction cartridges. HPLC analysis 
was carried out on a Merck Hitachi liquid chromatography system consisting of a 
gradient pump (D-6200), an autosampler (AS-4000), a fluorescence detector (F1000). 
Standards controls and samples were incubated for 2 min with the OPA reagent (1 
mg/ml OPA in borate buffer, pH 9.5, containing 0.1% 3-mercaptopropionic acid) 
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before automatic injection in the HPLC. The OPA-derivatives were separated on 
Waters Symmetry C18 column (4.6 x 150 mm, 5 m) with fluorescence monitor set at 
ex = 340 nm and em = 455 nm. The column temperature was kept at +30 C. Samples 
were eluted from the column with 50 mM K-phosphate buffer, pH 6.5 and 8.7% 
acetonitrile (v/v), at a flow rate of 1.1 ml/min. 
4.3.2.4 High sensitive C-reactive protein analysis 
Serum samples were analyzed by Immage automated analyzer using Beckman 
Coulter High Sensitivity C-Reactive Protein (CRPH) reagents (Beckman-Coulter, 
Fullerton, CA, USA) with working range of 0.2 to 1440 mg/l. The serum samples 
were analyzed according to the instructions of the manufacturer. 
4.3.2.5 Interleukin-6 analysis 
IL-6 was analyzed by R&D Systems Quantikine HS Human IL-6 Immunossay Kit 
(Minneapolis, USA) with working range of 0.156 to 10 pg/ml. Serum samples were 
analyzed according to the instructions of the manufacturer. Calibrators (supplied by 
the manufacturer) were analyzed in duplicate and samples as a single 
measurements. The absorbance at 490 nm was measured using a microplate reader 
(Tecan SPECTRAFluor, Tecan Group Ltd., Maennedorf, Switzerland). 
4.3.2.6 Tumour necrosis factor-α analysis 
Serum samples were analyzed with the R&D Systems Quantikine HS Human TNF-
α/TNFSF1A Immunossay Kit (Minneapolis, USA) with working range of 0.5 to 32 
pg/ml. The serum samples were analyzed according to the instructions of the 
manufacturer. Calibrators (supplied by the manufacturer) were analyzed in 
duplicate and samples as a single measurements. The absorbance at 490 nm was 
measured using a microplate reader (Tecan SPECTRAFluor, Tecan Group Ltd., 
Maennedorf, Switzerland). 
4.3.3 Ultrasound Imaging 
Ultrasound studies were performed using Sequoia 512 ultrasound mainframes 
(Acuson) (Figure 7) with the same method in both the Cardiovascular Young Finns 
Study and the study conducted in Kuopio University Hospital. In the assessment of 
brachial artery FMD, the left brachial artery diameter was measured both at rest and 
after reactive hyperemia. Increased flow was induced by inflation of a pneumatic 
tourniquet placed around the forearm to a pressure of 250 mmHg for 4.5 min, 
followed by release. Three measurements of arterial diameter were performed at 
end-diastole at a fixed distance from an anatomic marker at rest and at 40, 60, and 80 
s after cuff release. The vessel diameter in scans after reactive hyperemia was 
expressed both as the change in absolute diameter (FMD) and as the percentage 
relative to the resting scan (FMD%). 
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                  (a) 
 
 
 
(b)                                                                  (c)                
Figure 7. Assessment of brachial artery flow mediated vasodilation (a). Brachial 
artery at baseline (b). Brachial artery after shear stress (c). FMD%= ((4.16-
3.76)/3.76) x100=10.6 %≈11% 
4.3.4 Statistical Analysis 
The results are presented as means ± SD or when the distribution is not normal or 
when the variation was large, then the median values and minumums and 
maximums are used. The Kolmogorov-Smirnov test was used to evaluate data 
normality. The significance of differences was assessed by two independent samples 
t-test for observations that were normally distributed and when appropriate by 
nonparametric tests (Mann-Whitney U-test). When more than 2 groups were 
compared, the nonparametric Kruskall-Wallis test was used with Bonferroni 
correction. Univariate correlations were performed using the Pearson correlation. 
Multivariate analysis with linear regression was used to determine independent 
predictors of FMD. A p-value <0.05 was considered statistically significant. The 
sample size calculation revealed that 380 pregnant women would have been needed 
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in each ADMA tertile group to detect significant differences in FMD%. The SPSS 
version 19 (Chicago, IL, USA) was used in the statistical analysis.  
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5 Results 
The results of flow mediated brachial artery vasodilation in studies I-V are presented 
in table 4. The main results are presented in the table 5.  
 
Table 4. FMD% in studies I-V 
 
Study Study group FMD % in 
pregnancy 
FMD% 
nonpregnant/
postpartum 
Cardiovascular Risk In 
Young Finns Study 
Normal controls  9.5 
Normal pregnant 
First trimester 
 
7.4  
 
Second trimester 10.9   
Third trimester 11.1   
 
The Complicated 
Pregnancy Study 
 
Normal 
 
8.8  
 
7.9  
Hypertension  10.0 8.5 
Preeclampsia 11.0 7.2 
GDM (diet) 7.7 8.8  
GDM (insulin) 8.7 6.1  
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Table 5. The main results in studies I-V. 
 
Study Main finding Results Other findings 
I FMD was enhanced in 
pregnant women compared 
to nonpregnant 
1st trimester 0.22 mm 
(7.4%) 
2nd trimester 0.34 
mm (10.9%) 
3rd trimester 0.36 mm 
(11.1%) 
nonpregnant 0.29 
mm (9.5%) P=0.008 
(0.067) 
Pregnancy related marked 
hyperlipidemia 
 
FMD correlated with gestational 
age (r=0.345, P=0.010) 
II ADMA-concentrations were 
lower in pregnant women 
than in nonpregnant 
controls 
0.513 vs. 0.577 
µmol/l (P<0.001) 
ADMA levels did not explain the 
improved FMD during pregnancy 
III HsCRP concentration was 
greater during pregnancy 
than in nonpregnant 
controls 
2.52 mg/l vs. 1.21 
mg/l (P<0.001) 
Levels of IL-6 increased and 
TNF-α decreased (NS) in 
pregnant women 
Association between IL-6 and 
FMD in pregnancy 
IV FMD% was not attenuated 
in hypertensive pregnancies 
compared to normal 
pregnancies  during or after 
pregnancy 
11 % vs. 8.8 % 
(P=0.194) and 
postpartum 8.0 % vs. 
7.9 % (P=0.978) 
Markers of inflammation were 
high during pregnancy especially 
in hypertensive pregnancies vs. 
postpartum (medians):  
hs-CRP 4.5 vs. 0.80 mg/l 
(P=0.023) 
IL-6 2.1 vs. 1.2 pg/ml (P0.006) 
TNF-α 1.9 vs. 1.5 pg/ml 
(P=0.030) 
V In both diet and insulin 
treated gestational diabetes 
FMD remained good   
diet 7.7 % vs. insulin 
8.7 % vs. control 
8.8% (P=0.597) 
During pregnancy,  lipids were 
similar in GDM and control 
groups irrespective of 
significantly higher BMI in GDM 
group but postpartum lipids and 
glucose levels were significantly 
higher and weight loss was 
diminished in GDM group 
5.1  NORMAL PREGNANCY 
 
5.1.1 Flow mediated vasodilation in normal pregnancy 
Endothelium-dependent FMD during reactive hyperemia increased towards the end 
of pregnancy despite increasing serum lipid concentrations in the cross-sectional 
Cardiovascular Risk in Young Finns Study. The increase in the absolute value of 
FMD was statistically significant in pregnant women compared to nonpregnant 
controls (P=0.008). The value of FMD in the first trimester was diminished as 
compared with the non-pregnant controls and the increase in FMD% was 
statistically significant over the 3 trimesters (P=0.04). In pregnancy, FMD% 
correlated directly with gestational age, vessel size, total cholesterol (TC) and 
triglycerides (TG), but not with LDL or HDL. In the nonpregnant women, FMD% 
did not correlate with any of the serum lipid values. Overall, the univariate 
correlation analysis between FMD% and the other parameters during pregnancy 
revealed a significant correlation for maternal serum TC, TG and vessel size, 
whereas in non-pregnant women, the vessel size was the only significant correlate of 
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FMD%. A multiple regression analysis was used to identify the independent 
variables best predicting FMD% during pregnancy: these were TG and vessel size. 
In the Complicated Pregnancy Study endothelial function was longitudinally 
determined in 32 normal pregnant women at gestational age of 24-38 weeks. The 
FMD% in normal pregnant women was 8.8. % during pregnancy and 7.9 % after 
pregnancy, the difference was not statistically different (P=0.439).  
5.1.2 Lipid concentrations in normal pregnancy 
Lipid profiles showed that in the third trimester of pregnancy, the mean 
concentrations of TC, LDL-C, HDL-C, TG and VLDL-C increased by 36, 35, 26, 116 
and 115% respectively, when compared with the values of non-pregnant women. 
The presence of marked hypercholesterolemia associated with the increased HDL-C 
concentrations is common during pregnancy and 38% (21/56) of the pregnant 
women had a serum TC concentration exceeding 7.0 mmol/L.  
5.1.3 Asymmetric dimethylarginine concentration in normal pregnancy 
The mean ADMA concentration was significantly lower in pregnant women 
compared with the non-pregnant controls (0.513 ± 0.0593 versus 0.577 ± 0.0710, P < 
0.001). The L-arginine concentration was also significantly lower in pregnant women 
than in their nonpregnant counterparts. To evaluate the effects of serum ADMA 
concentrations in normal pregnancy to endothelial function, ADMAMoM values 
were calculated based on the median of each of the three trimesters. These 
MoMvalues were then divided into tertiles and correlated to FMD. The three groups 
were: low ADMA [ 1 MoM (lowest ‒ 0.967 MoM)], intermediate ADMA [2 MoM 
(0.968 ‒ 1.0427] and high ADMA [3 MoM (1.0428 ‒ highest MoM)]. We found no 
statistically significant relationship between maternal serum ADMA concentrations 
and endothelial function.  
5.1.4 High sensitive C-reactive protein and proinflammatory cytokines in normal 
pregnancy 
The median IL-6 concentration was 1.66 in pregnancy when all three trimesters were 
pooled vs. 1.32 pg/ml when compared to the non-pregnant (NS). In pregnancy the 
median TNF-α concentration was 2.11 vs. 2.38 pg/ml in the non-pregnant group 
(NS). During pregnancy, the median hsCRP concentration was 2.52 mg /l whereas 
the non-pregnant women had a median hsCRP concentration of 1.21 mg/l (P<0.001). 
Women using oral contraceptives (OCs) (25⁄62) in the control group displayed 
increased hsCRP concentrations compared to those not using OCs (median 0.71 mg/l 
for controls versus 1.92 mg/l for OC users, P = 0.002). In smoking women the median 
hsCRP value was 3.19 mg /l in pregnancy (n = 6) versus 2.63 mg/l in the non-
pregnant group (n = 6) (NS). Exclusion of smokers from the analysis did not change 
the results: hsCRP was increased in pregnant women (P = 0.002) compared to non-
pregnant women (median 1.17 (0.10–23.9) in non-pregnant versus 2.52 (0.44–23.6) 
mg/l in pregnant women). IL-6 showed a positive correlation to the FMD in pregnant 
women, R = 0.288, P = 0.031. In non-pregnant women, IL-6 correlated to baseline 
diameter (R = 0.336, P = 0.008). The results of flow mediated dilation, ADMA and hs-
CRP and the cytokines are presented in the table 6. In addition FMD%, the 
concentrations of hs-CRP and cytokines in The Cardiovascular Risk in Young Finns 
Study are shown in figure 8. 
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Table 6. Flow mediated vasodilation and the concentrations of asymmetric dimethylarginine, 
high sensitive C-reactive protein, tumor necrosis factor-α and interleukin-6 in normal pregnant 
patients. 
Normal pregnancy 
Study The Cardiovascular Risk in Young Finns Study The Complicated 
Pregnancy Study 
Gestational 
 age 
1st trimester 2nd trimester 3rd trimester P weeks 24-38 
FMD%  
(mean ± SD) 
7.4  
± 3.5 
10.9  
±  4.6 
11.1  
± 5.3 
NS 8.8  
± 5.1 
FMD (mm)  
(mean ± SD) 
0.29  
± 0.12 
0.22  
± 0.10 
0.34  
± 0.13 
0.008 0.36  
± 0.036 
ADMA (µmol/l) 
(mean ± SD) 
0.521  
± 0.0745 
0.505  
± 0.0459 
0.513 
± 0.0638 
NS  
hs-CRP (mg/l) 
(median, min., 
max.) 
2.43  
(0.52 − 15.5)  
2.92  
(0.78 − 16.9) 
2.01  
(0.62 − 6.38) 
NS 3.0  
(0.54 − 13.4) 
IL-6 (pg/ml)  
(median, min., 
max.) 
1.26  
(0.48 − 3.1) 
1.28  
(0.62 − 6.38) 
1.80  
(0.56 − 5.6) 
NS 1.8  
(0.64 − 5.4) 
TNF-α (pg/ml) 
(median, min., 
max.) 
2.11  
(1.45 − 4.1) 
2.09  
(0.69 − 34.7) 
2.28  
(1.28 − 5.4) 
NS 2.0  
(1.2 − 4.1) 
Figure 8.  Medians of TNF-α, IL-6 and hs-CRP and means of FMD% in non-pregnant 
and pregnant women in the Cardiovascular Risk in Young Finns Study. 
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5.2 COMPLICATED PREGNANCY 
 
5.2.1 Hypertensive pregnancies 
 
Endothelial function during pregnancy was similar in pregnancy-related 
complications such as hypertension and preeclampsia and GDM when compared to 
normal pregnant women.  The mean FMD% was 11.0% in the pooled group of 
hypertensive women and 8.8% in normal pregnant women during pregnancy 
(P=0.194) and 8.0% versus 7.9% postpartum (P=0.978). Concentrations of markers of 
inflammation were markedly increased in pregnant hypertensive group compared to 
those after delivery (hsCRP 4.5 versus 0.80 mg/l, P=0.023, IL-6 2.1 versus 1.2 pg/ml, 
P=0.006; TNF-α 1.9 versus 1.5 pg/ml, P=0.030). When compared the hypertensive 
pregnancies to the normal pregnancies the markers of inflammation were similar 
during and after pregnancy. FMD% in hypertensive pregnancies is presented in 
table 7 and markers of inflammation in table 8. 
 
5.2.2 Gestational diabetes 
 
FMD% among adequately managed GDM patients in either the dietary or the insulin 
treatment group compared to controls during pregnancy was not attenuated (7.7% 
and 8.7 % vs. 8.8 % concomitantly, NS) After the pregnancy FMD% in the former 
dietary GDM group was 8.8% and in the insulin treated group it was 6.1 % (only one 
person attended postpartum) vs. 7.9 %, (NS). Table 7 shows the results of the flow 
mediated dilation in the GDM pregnancies.  
In a similar way, but in lesser extent GDM patients showed higher concentrations 
of markers of inflammation during pregnancy, see table 8. There were no statistically 
significant associations between the markers of inflammation and FMD. 
During pregnancy, lipid values in the GDM group did not differ from the controls 
despite the glucose intolerance. Three months postpartum, BMI, fasting glucose and 
all lipids were significantly elevated in the GDM group, but this was not associated 
with endothelial dysfunction. The BMIs, glucose and lipis values for GDM groups 
are presented in table 9. 
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Table 7. FMD% in pregnancy complications. 
 
Pregnancy complication Hypertensive GDM 
(diet) 
GDM 
(insulin) 
Controls 
FMD% mean ± SD in pregnancy 
weeks 24-38 
11 ± 6.3 7.7 ± 6.0 8.7 ± 5.2 8.8 ± 5.1 
Postpartum 8.0 ± 4.2 8.8 ± 5.2 6.1 7.9 ± 3.5 
 
 
Table 8. Hs-CRP and proinflammatory cytokine levels in women with hypertensive disorder  
during pregnancy or GDM (median, minimum, maximum). 
 
Parameter  Hypertensive GDM 
hs-CRP (mg/l)  4.5 (0.89 − 38) 2.27 (0.199 − 8.3) 
Postpartum 0.80 (0.27 − 5.9) 1.69 (0.199−7.04) 
IL-6 (pg/ml) 2.1 (0.70 − 11) 2.32 (0.795−8.09) 
Postpartum 1.2 (0.73 − 3.0) 1.83 (0.293−11.477) 
TNF-α (pg/ml) 1.9 (0.88 − 3.2) 1.51 (0.778 − 2.91) 
Postpartum 1.5 (0.71 − 2.1) 1.29 (0.673 − 4.01) 
 
 
 
Table 9. BMIs, fasting glucose and lipids in GDM women during and after pregnancy. 
 
Group GDM diet GDM insulin 
 Pregnancy Postpartum Pregnancy Postpartum 
BMI 28 ± 5.5 29 ±  5.42 31 ± 8.3 29 ± 2.70 
fB-Gluc 
(mmol/l) 
4.9 ± 0.36 5.4  ± 0.53 5.6 ± 1.5 6.7 ± 3.8 
TC (mmol/l) 6.27 ± 1.07 5.01 ± 0.670 6.02 ± 1.42 5.49 ± 0.863 
LDL (mmo/l) 3.74 ± 0.937 3.15 ± 0.680 3.63 ± 1.14 3.61 ± 0.953 
HDL (mmol/l) 1.84 ± 0.492 1.38 ± 0.388 1.75 ± 0.237 1.23 ± 0.243 
Trigly (mmol/l) 2.60 ± 0.901 1.21 ± 0.841 2.98 ± 1.24 1.59 ± 1.57 
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6 Discussion 
The purpose of this study was to examine the vascular changes occurring during 
pregnancy, especially in preeclampsia. It was hypothesized that when compared to 
normal pregnant women the endothelium in preeclampsia would be injured. We 
have collaborated with Cardiovascular Risks in Young Finns Study-group to 
determine the FMD in normal pregnancies and had access to a considerable amount 
of data with regard to classical cardiovascular risk factors. At the same time material 
was collected from Kuopio University Maternity Clinic, although patients with 
pregnancy complications were harder to collect than expected. 
Why was FMD chosen? This technique provides a noninvasive and direct 
measure of artery function and health in vivo and it is suitable for investigating large 
populations (as in Cardiovascular Risk in Young Finns Study). Further this 
technique can easily be conducted during pregnancy. The selected method is well 
validated and its reproducibility has been evaluated. There is increasing evidence 
that FMD provides valuable and independent prognostic information in humans. 
However, different methodological approaches limit its validity, comparability, and 
its potential use as a clinical and physiological research tool. Improving 
understanding of the physiological and technical principles on which the FMD 
technique is based will improve its application and interpretation of 
(patho)physiological changes that may occur between groups or after 
interventions(Thijssen, et al. 2011). 
The main strength of the Young Finns Study is that it is a prospective cohort 
study, i.e. it represents the total population. These results can be generalized to 
white Caucasian pregnant women. OC users were not excluded from the control 
group, as there is data that FMD% was similar in OC users and non-OC users in the 
Cardiovascular Risk in Young Finns Study(Valtonen, et al 2010). In the first three 
studies we compared the vascular health of pregnant women to that of nonpregnant 
controls; this can cause an error due to the fact that pregnant women usually try to 
adopt a healthier lifestyle than their nonpregnant counterparts. In studies IV-V the 
same individuals could be compared during and after pregnancy. It has to be taken 
into account that there is marked individual and even interindividual variability in 
FMD measurements. In all the presented studies sample sizes are small and a type II 
error is possible. If one wanted to detect potential weak associations between FMD 
and investigated variables, much larger studies involving several thousands of 
subjects should be carried out. There was some loss of participants in The 
Complicated Pregnancy Study which reduced the sample size postpartum, many of 
the patients were hesitant to participate with the newborn baby. Dropouts may have 
affected the statistical analysis e.g. the nonsignificant result when comparing FMD% 
during and after pregnancy. 
Endothelial function improved towards the end of normal pregnancy, despite the 
presence of marked hyperlipidemia. These results show that the elevated serum 
concentrations of TC, TG, LDL-C, and VLDL-C did not evoke endothelial 
dysfunction during pregnancy. On the contrary, endothelial function improved in 
the second and third trimesters of the pregnancy, probably partly because of the 
increased concentration of HDL-C, which may have inhibited the oxidation of low-
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density lipoprotein and thus protected the endothelium. Interestingly the CVD risk 
in multiparous women later in life has been reported to be increased(Beral. 1985) or 
reduced in other studies(Jacobs, et al. 2012). The physiological short-term increase in 
the levels of serum lipids and the improvement of endothelium-dependent 
vasodilation responses are associated with gestation rather than with each other. The 
improvement of endothelial function in pregnancy in the Cardiovascular Risk in 
Young Finns Study was significant in terms of FMD but not as great as reported in 
previous studies(Dorup, et al. 1999) (Savvidou, et al. 2000) (Faber-Swensson, et al. 
2004) (Seeliger, et al. 2011). In our longitudinal Complicated Pregnancy Study, 
FMD% was enhanced, although not significantly, in pregnancy vs. postpartum, 
which is in line with one previous study(Quinton, et al. 2007). Previously, in normal 
pregnancy mean FMD% has been reported to be 8.84 ± 3.18% between 10-30 weeks, 
which was significantly higher than in non-pregnant controls (6.42 ± 
2.45%)(Savvidou, et al. 2000). In the Cardiovascular Risk In Young Finns Study the 
cross-sectional control group of 62 women had better FMD% (9.48%) than in 
Savvidou’s study with 19 controls. In the first trimester FMD% has previously been 
reported to be smaller than in the second trimester, which is in line with our results.  
After 30 weeks FMD% has been found to decrease to prepregnancy levels (Savvidou, 
et al 2000) but this is in contrast to our results from the Cardiovascular Risk in Young 
Finns Study. On the other hand this might explain the insignificant increase in 
FMD% in the Complicated Pregnancy Study as the FMD was investigated during 
gestational weeks 24-38. 
It seemed that lowered maternal serum ADMA and L-arginine concentrations did 
not modulate endothelial function during normal pregnancy in our study. The 
possibility of a type II error has to be taken into consideration when interpreting 
these results. However, according to the estimation of the sample size in retrospect, 
it was found that more than 1140 pregnant subjects would have needed to be studied 
in order to make statistically significant the weak association between ADMA and 
FMD. This is in line with a result based on the evaluation of an entire population in 
the Young Finns Study with respect to ADMA and FMD%(Juonala, et al. 2007). 
Rixos, et al. measured ADMA concentrations in the three trimesters of 41 
uncomplicated pregnancies, and the result s are similar to ours: 0.51 ± 0.14, 0.52 ± 
0.13, 0.58 ± 0.16 μmol/l(Rizos, et al. 2011). They also assessed ADMA concentrations 
in 10 pregnant women with preeclampsia and found a significant increase in the 
second trimester concentrations of ADMA when compared to the normal pregnant 
women (0.58 ± 0.10, 0.63 ± 0.14 (P=0.02), 0.68 ± 0.11 μmol/l). In 14 pregnancies with 
SGA infant the ADMA concentrations were significantly lower in each trimester 
(0.40 ± 0.10 (P=0.005), 0.42 ± 0.10 (P=0.0077), 0.45 ± 0.10 (P=0.007) μmol/l(Rizos, et al. 
2011). 
The concentrations of IL-6 and TNF-α did not change significantly from the non-
pregnant state to the pregnant condition or during the three trimesters of pregnancy 
and thus these changes are unlikely to account to the pregnancy-related increased 
flow mediated dilation. The median concentration of TNF-α and IL-6 were 2.1 and  
1.3 pg/ml in first trimester according to our results and 1.1 and 3.7 pg/ml according 
to a study of  100 normal pregnant women under 20 weeks(Fiorini, et al. 2012). 
Substatially higher concentrations have also been reported for IL-6 (8.1 pg/ml) and 
similar to TNF-α (1.3 pg/ml)(Coussons-Read, et al. 2012). We found a significant 
increase in the serum hsCRP concentration of normal pregnant women, and this is in 
line with the literature(Coussons-Read, et al. 2012). Incerased hs-CRP did not cause 
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endothelial dysfunction. The enhancement of endothelial function appears to occur 
despite the proinflammatory state, most probably due to an exaggerated NO 
response, which is specific to pregnancy itself. 
Based on earlier studies one would have expected to find endothelial dysfunction 
in complicated pregnancies. Endothelial function has been found to be attenuated in 
severe preeclampsia before the signs of clinical disease in early pregnancy 
(Savvidou, et al. 2003) and even 5-6 years after moderate/severe 
preeclampsia(Lampinen, et al. 2006). On the contrary this present study showed that 
endothelial function in conduit arteries was similar in normal and in hypertensive 
pregnancies. In both groups, endothelial function was better during pregnancy than 
postpartum, and in hypertensive pregnancies endothelial vasodilation after a 
stimulus was even better than in normal pregnancies. There were no detectable signs 
of endothelial dysfunction in brachial artery in hypertensive pregnancies and in 
mild-to-moderate preeclampsia. The effect of medication on endothelial function 
among hypertensive women was not analysed, 16/26 women had a medication for 
hypertension. It is possible that the increased blood flow due to sympathetic 
overactivation and increased blood pressure in hypertensive pregnancies results in 
increased shear stress and thus an even greater increase in shear-stress mediated 
increased vasodilation. In a previous study, pulsed Doppler findings of maternal 
uterine artery, maternal ophthalmic artery, and brachial artery flow-mediated 
vasodilation varied among women with preeclampsia showing that there were 
vascular changes concomitantly or separately in uterus, ophthalmic vessels and 
conduit arteries(Takata, et al. 2002). The reason for this discrepant result might be 
the different vascular beds: In the microvascular bed, endothelial dysfunction is 
readily detectable and the oedema caused by leaking endothelium could interfere 
with the measurements.  
The compromised nitric oxide production causing vasoconstriction is not the only 
mechanism leading to pregnancy-induced hypertension or preeclampsia(Powe, et al. 
2011), and increased FMD was found also in late hypertensive pregnancies. This can 
also be explained by the selection of the material, as it is almost impossible to 
examine patients with severe preeclampsia and in our study the hypertension and 
preeclampsia appeared in the late pregnancy. From the clinical point of view early-
onset (under 30 weeks) and late-onset preeclampsia are distinct 
syndromes(Valensise, et al. 2008). Similar findings were recently published in a 
retrospective study where only women with severe preeclampsia and IUGR had 
impaired vasodilatory function 6-24 months after pregnancy, and patients with late-
onset preeclampsia had a comparable FMD to their control counterparts (3.2 ± 2.7% 
and 2.1 ± 1.2% versus 7.9 ± 3.8% and 9.1 ± 3.5%, respectively; P<0.0001)(Yinon, et al. 
2010). 
We found that even in normal pregnancies, the third trimester concentrations of 
hsCRP, IL-6, and TNF-α were increased as compared to the postpartum values. The 
difference during pregnancy was not statistically significant between normal and 
hypertensive pregnancies though increases in hsCRP and IL-6 concentrations were 
observed in hypertensive pregnancies. This negative result may have occurred due 
to a type 2 error, i.e. the sample size was too small to confirm the difference. From 
pregnancy to 3-month postpartum, all the investigated markers of inflammation 
declined significantly in the hypertensive women. The result confirms the 
hypothesis that pregnancy-induced hypertension and preeclampsia represent, at 
least to some degree an inflammatory response to the pregnancy(Can, et al. 2011). 
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However, the markers of inflammation were measured from systemic blood samples 
and thus the results do not necessarily represent the actual concentrations within 
various tissues as the cytokines are often released locally. 
This study is the first of its kind to show that in adequately managed gestational 
diabetes, endothelial function remains good despite the metabolic disorder. In the 
years 2003-2008 when the patients were recruited from Kuopio University Hospital 
the OGTT was considered abnormal when 0-1-2 hour values were ≥ 4.8-11.2-9.9 
mmol/l measured from venous plasma. The fasting glucose value was pathological 
in 91.7 % of GDM patients in the present study. The low cut-off value for fasting 
glucose may explain partly the result: the endothelial function was not attenuated 
because part of the GDM patients would be considered normal according the 
diagnostic criteria for GDM today (glucose ≥ 5.3 − 10.0 − 8.6 mmol/l from capillary 
plasma). Somewhat contradictory findings have also been published; FMD% was 
attenuated in ten women with GDM and also in 13 women with reduced insulin 
sensitivity when compared to normal pregnant women(4.1 ± 0.9 vs. 7.6 ± 1.1 v.s. 10.9 
± 1.1) (Paradisi, et al. 2002). In that study OGTT and assessment of FMD% were 
completed simultaneously, so the effect of treatment might explain the different 
results. In addition to its actions in glucose and lipid metabolism insulin is involved 
in regulation of NO production in endothelial cells and when insulin is administered 
intravenously it acts as weak vasodilator(Yki-Järvinen, Utriainen. 1998) Resistance to 
insulin action associates with endothelial dysfunction(Yki-Järvinen. 2003). According 
to our results it seems that in GDM, if the newly appearing insulin resistance is well 
controlled by diet or insulin therapy, then the mild hyperglycemia does not cause 
endothelial dysfunction in the conduit arteries during pregnancy. While this can be 
viewed as good news for the mother, even mild hyperglycaemia can cause adverse 
consequences to the foetus, such as foetal demise and macrosomia and complications 
at birth or during the neonatal period(Reece. 2010). 
One very interesting finding was that the good metabolic control during 
pregnancy in GDM women was lost already three months after delivery. This was 
reflected by the diminished weight loss, elevated blood pressure and worsened lipid 
profile and elevated fasting blood glucose level, increasing the future risks for type 2 
diabetes and cardiovascular disease. Insulin therapy was terminated when the baby 
was born. It is evident that after parturition, the women were no longer adhering to 
a stringent diet anymore.  
The levels of proinflammatory cytokines were higher during pregnancy than 
postpartum especially in normal but also in GDM women. Although GDM women 
had greater BMI values, they had significantly lower Hs-CRP levels than normal 
pregnant women. After pregnancy, the differences disappeared and the circulating 
levels of the proinflammatory cytokines declined. Both normal pregnant women and 
women with metabolic disorder displayed an inflammatory response in pregnancy, 
but this did not seem to correlate with the endothelial function. 
It seems that endothelial function is attenuated after severe preeclampsia and 
IUGR but not after mild to moderate preeclampsia and hypertensive or GDM 
pregnancy. The association between CVD risk factors and endothelial dysfunction 
cannot be expressed in simple ways, because there are still unknown 
vasculoprotective or genetic factors that can alter the results. These variables may be 
related to pregnancy and they seem to protect the endothelium even in complicated 
pregnancy. 
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7  Summary and future research needs 
This study confirms that in normal pregnancy, endothelial function is enhanced, 
despite the many associated risk factors that in nonpregnant state would lead to 
endothelial dysfunction and signs of preclinical arteriosclerosis. Asymmetric 
dimethylarginine (ADMA) concentrations were significantly lower in pregnant 
women but this did not explain the improved FMD in the correlation analysis. 
Endothelial function in normal pregnancy was not attenuated despite the significant 
increase in hsCRP, and pregnancy related changes in the concentrations of TNF-α 
and IL-6 were non-significant.  
Women with third trimester hypertensive pregnancies and mild-to-moderate 
preeclampsia and also GDM women exhibited similar flow mediated vasodilation 
during and three months after pregnancy when compared to normal pregnant 
women. GDM patients displayed metabolic disturbances and increased BMI 
compared to controls after pregnancy. 
The precise mechanisms behind the enhanced endothelial function in pregnancy 
are still unclear, though a considerable amount of studies have been published in the 
field of normal and complicated pregnancy and endothelial function These studies 
have included in vitro work, where the endothelial cells from the vessels of pregnant 
or preeclamptic women have been examined and the eNOS and and NO measured, 
or Ca++ -concentrations in the cell or gap junctions investigated. Clinical studies with 
pregnant women are conducted mostly in very small study populations because of 
ethical and practical difficulties and thus the outcomes can be confusing since 
selection and publication biases probably affect the results. Experimental animals do 
not experience preeclampsia, probably due to negative selection, i.e. the animal 
models cannot be extrapolated to preeclamptic women; though similar NO mediated 
vasodilation in pregnancy can be detected in animals. A genetic predisposition to 
preeclampsia is evident and studies in different populations have identified 
polymorphisms in PE candidate genes in women with pre-eclampsia(Valenzuela, et 
al. 2012). Identifying how the endothelial cells in normal pregnancy are 
reprogrammed would help to reveal the pathophysiology in preeclamptic 
pregnancies and perhaps improve the treatment of this disease. In general, the 
enhancement of endothelial function encountered during pregnancy could also be 
applied to other common forms of hypertension. 
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Attenuated endothelial function is 
associated with cardiovascular risk 
factors and is considered as preclini-
cal sign of cardiovascular disease. 
Pregnancy related complications such 
as hypertensive disorder in pregnancy, 
preeclampsia and gestational diabetes 
and cardiovascular disease share many 
risk factors. This study was undertaken 
to explore endothelial function in nor-
mal pregnancy as well as in pregnancy 
related complications. Endothelial 
function was assessed with brachial 
artery flow mediated dilation as a 
part of the on-going population based 
Cardiovascular Risk Factors in Young 
Finns Study and in the Complicated 
Pregnancy Study in Kuopio University 
Hospital conducted in 2003-2008.
